PerkinElmer Expands Screening and Drug Discovery Relationship with AstraZeneca
This agreement follows a six-year collaboration between the two companies. The screening contract will be deployed at PerkinElmer's Assay and Screening Service Center of Excellence in Montreal.
"Because of the success of the screening program and the consistent high level of service we have received from PerkinElmer, we are pleased to expand our relationship into broader high throughput screening activities," said Philippe Walker, Ph.D., vice-president, Discovery at AstraZeneca R&D Montreal. "We are confident that our partners at PerkinElmer will continue to provide integrated, powerful screening solutions as we look to maximize our drug discovery programs."
AstraZeneca's "Directed Library Screening" approach involves the rapid testing of combinatorial libraries against a panel of diverse GPCR targets. Based on the results, new sets of compounds are designed and synthesized by AstraZeneca, which are then tested by PerkinElmer in a panel of GPCRs. This iterative process enables AstraZeneca to rapidly identify potent and selective compounds for critical targets. In addition to the Directed Library Screening program, the new contract includes an expanded offering of functional HTS assays based on PerkinElmer reagent platforms, such as AlphaScreen(TM), ScreenReady Targets and Membrane Target Systems, as well as sample preparation and detection platforms, such as TopCount(R), PlateTrak(TM), ImageTrak(TM) and MultiPROBE(R).
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.